Skip to main content
Article thumbnail
Location of Repository

CCN2 Enhances Resistance to Cisplatin-Mediating Cell Apoptosis in Human Osteosarcoma

By Hsiao-Chi Tsai, Chun-Yin Huang, Hong-Lin Su and Chih-Hsin Tang


Osteosarcoma (OS) is the most common form of malignant bone tumor and is an aggressive malignant neoplasm exhibiting osteoblastic differentiation. Cisplatin is one of the most efficacious antitumor drugs for osteosarcoma patients. However, treatment failures are common due to the development of chemoresistance. CCN2 (also known as CTGF), is a secreted protein that binds to integrins, modulates the invasive behavior of certain human cancer cells. However, the effect of CCN2 in cisplatin-mediated chemotherapy is still unknown. Here, we found that CCN2 was upregulated in human osteosarcoma cells after treatment with cisplatin. Moreover, overexpression of CCN2 increased the resistance to cisplatin-mediated cell apoptosis. In contrast, reduction of CCN2 by CCN2 shRNA promoted the chemotherapeutic effect of cisplatin. We also found that CCN2 provided resistance to cisplatin-induced apoptosis through upregulation of Bcl-xL and survivin. Knockdown of Bcl-xL or survivin removed the CCN2-mediated resistance to apoptosis induced by cisplatin. On the other hand, CCN2 also promoted FAK, MEK, and ERK survival signaling pathways to enhance tumor survival during cisplatin treatment. In a mouse xenograft model, overexpression of CCN2 promoted resistance to cisplatin. However, knockdown of CCN2 increased the therapeutic effect of cisplatin. Therefore, our data suggest that CCN2 might be a critical oncogene of human osteosarcoma for cisplatin-resistance and supported osteosarcoma cell growth in vivo and in vitro

Topics: Animals, Antineoplastic Agents, Apoptosis, Bone Neoplasms, Cell Death, Cell Line, Tumor, Cisplatin, Connective Tissue Growth Factor, Disease Models, Animal, Drug Resistance, Neoplasm, Focal Adhesion Protein-Tyrosine Kinases, Gene Expression Regulation, Neoplastic, Humans, Inhibitor of Apoptosis Proteins, MAP Kinase Signaling System, Osteosarcoma, Tumor Burden, Xenograft Model Antitumor Assays, bcl-X Protein
Year: 2015
DOI identifier: 10.1371/journal.pone.0090159
OAI identifier:

Suggested articles

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.